Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study of PLX-200 for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis

Next Previous
Trial Profile

A Clinical Study of PLX-200 for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PLX 200 (Primary)
  • Indications Neuronal ceroid lipofuscinosis
  • Focus Adverse reactions
  • Sponsors Polaryx Therapeutics

Most Recent Events

  • 20 Jan 2020 According to a Polaryx Therapeutics media release, the company has received an Investigational New Drug Application (IND) approval from the U.S. Food and Drug Administration (FDA) for the treatment of Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) patients with PLX-200.
  • 30 Dec 2019 New trial record
  • 22 Dec 2019 According to a Polaryx Therapeutics media release, the Company has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for the treatment of patients with Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL).The company will start this trial as soon as possible.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top